For years, Congress has signaled that it desires to crack down on Pharmacy Profit Managers, the center males which have come underneath hearth for his or her vertical integration with insurers and their function in spiking drug prices.
This week, it lastly occurred by way of the Consolidated Appropriations Act of 2026, prompting employer teams together with the Purchaser Enterprise Group on Well being (PBGH) and the ERISA Trade Committee to cheer its passage.
“Taken collectively, the bipartisan well being care reforms on this legislation will decrease well being care prices for employers and staff alike, introduce new accountability for PBMs, and can ship purchasers an unprecedented quantity of transparency into their pharmacy profit plan,” in accordance with a press release from PBGH.
However the actuality is extra sophisticated. Whereas it’s true that there have been main good points made by employers, probably the most important components of the legislation — the delinking of PBM compensation from the value of a drug in Medicare Half D — eluded employer teams. It is a provision within the new legislation that solely applies to Medicare Half D, in accordance with Jesse Dresser, a companion in Frier Levitt’s Life Sciences Division.
In Medicare Half D, unfold pricing was additionally prohibited as PBMs will not be capable of derive any income tied to the price of the drug, Dresser acknowledged. Unfold pricing happens when a PBM costs a well being plan extra for a drug than it pays the pharmacy and retains the distinction as revenue. The adjustments will take impact in 2028.
Employers, in the meantime, didn’t get a ban on unfold pricing, famous Shawn Gremminger, president and CEO of the Nationwide Alliance of Healthcare Purchaser Coalitions. Neither did they get the “longshot ask” of creating PBMs fiduciaries to their purchasers, which might require PBMs to behave in the perfect monetary curiosity of employers.
Nonetheless, this shouldn’t diminish what the legislation achieves, as it’s a “huge deal and can meaningfully change the best way PBMs function within the business house,” Gremminger mentioned.
If delinking from listing value, a ban on unfold pricing and PBMs not turning into fiduciaries to clients in the end failed within the last passage, what good points have been made?
What the legislation does embody for employers is a requirement for PBMs to offer extra detailed reporting to plan sponsors, akin to a listing of coated medicine distributed, prescriptions distributed by affiliated pharmacies and knowledge on biologics and biosimilars. As well as, PBMs are mandated to go alongside all rebates, reductions, charges and different funds they obtain on medicine on to employers or group well being plans.
“After eight years, ERIC-led reforms to the PBM trade that instill larger accountability and transparency made it throughout the aim line, and the end result can be decrease drug prices for greater than 160 million Individuals who get their medical health insurance by means of a job,” mentioned James Gelfand, president and CEO of the ERISA Trade Committee, in a press release.
This does put PBMs on the highway to larger transparency, however the battle is just not gained.
As Wendell Potter identified in his e-newsletter, employers may very well get a few of what they need by way of a rule the Division of Labor just lately proposed. The rule would require PBMs to reveal all rebates and different funds from producers to employer-sponsored well being plan fiduciaries, together with any compensation tied to the distinction between plan funds and pharmacy reimbursements. It additionally permits fiduciaries to audit these disclosures and gives protections if PBMs fail to conform.
“With the brand new Consolidated Appropriations Act of 2026, together with the Division of Labor’s proposed regulation, I do suppose that there can be some extra safety, extra aid geared toward compelling disclosure of sure info,” Dresser mentioned.
Nonetheless, in accordance with Gremminger, whereas the Division of Labor’s proposed rule and the Consolidated Appropriations Act of 2026 give purchasers “unprecedented transparency” into PBMs, employers nonetheless gained’t have every part they’re on the lookout for.
“Even after each the regulation and the legislation are carried out, PBMs will nonetheless be allowed to have interaction in unfold pricing and hyperlink their charges to the value of medication within the business market. PBMs will nonetheless not be statutory fiduciaries,” Gremminger mentioned. “The occasions of the previous week are an enormous leap ahead, however far more must be performed.”
Dresser additionally famous that it’s doable that the Division of Labor’s proposed rule could change down the road, particularly given the truth that it was launched in the identical week because the Consolidated Appropriations Act of 2026.
“A few of what they’re trying to do within the new rules is already being directed by legislation and likewise requires the enactment of rules geared toward imposing and implementing these new guidelines,” he mentioned. “So I do suppose that there’s a chance that this explicit iteration of the Division of Labor’s proposed regulation doesn’t undergo, however as an alternative it will get type of transformed into one thing that perhaps extra aligns with the just lately enacted legislation.”
He added that it’s unlikely for future iterations of the DOL rule to incorporate a ban on unfold pricing, as it will possible want congressional motion. Nonetheless, it’s doable it may come from company enforcement motion. He pointed to the latest FTC settlement with Categorical Scripts over insulin, through which Categorical Scripts agreed to a collection of adjustments, together with transferring away from a mannequin that includes rebates.
Firms that serve employers are additionally applauding the efforts made to rein in PBMs, together with Carrum Well being.
“We’re happy to see these developments within the method to PBM pricing and compensation as it’ll create extra transparency for employers,” mentioned Doug Cole, vice chairman of well being plan partnerships at Carrum Well being.
In the meantime, AJ Loiacono, CEO of Judi Well being (a tech-enabled PBM previously Capital Rx), agrees that it is a main step ahead, however acknowledges that extra must be performed. For instance, the legislation doesn’t deal with PBMs steering sufferers to affiliated specialty pharmacies or vertical integration. Judi Well being payments itself as a clear PBM.
“When PBMs personal mail-order and specialty pharmacies, they’ve monetary incentives to steer sufferers towards these channels—typically at greater price to the plan. Larger transparency into affiliate pharmacy pricing and utilization is a good begin, however structural separation could in the end be wanted,” he mentioned.
In different phrases, Loiacono is suggesting that PBMs be damaged up such that an insurance coverage firm, a PBM and a pharmacy don’t have the identical company mother or father, as is the case with many massive PBM gamers at the moment. That could be the longest shot of all of them.
Picture: cagkansayin, Getty Photographs
